NEW YORK – SomaLogic said on Monday that it has entered an agreement to merge with CM Life Sciences II, a special purpose acquisition company (SPAC) sponsored by affiliates of Casdin Capital and Corvex Management, with the purpose of listing on the Nasdaq Global Market.
Upon completion of the transaction, expected in the third quarter, CM Life Sciences II will be renamed and its common stock will list on the Nasdaq under the ticker symbol SLGC.